Cardiff Oncology (NASDAQ:CRDF) Issues Quarterly Earnings Results

Cardiff Oncology (NASDAQ:CRDF) released its quarterly earnings results on Thursday. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03, Zacks reports. Cardiff Oncology had a negative net margin of 9,344.14% and a negative return on equity of 77.94%.

Cardiff Oncology Trading Up 0.4%

CRDF traded up $0.01 during trading on Thursday, hitting $2.25. 612,673 shares of the company traded hands, compared to its average volume of 762,118. The company has a market cap of $149.69 million, a PE ratio of -2.59 and a beta of 1.68. The stock’s 50-day simple moving average is $2.17 and its two-hundred day simple moving average is $2.80. Cardiff Oncology has a 1 year low of $1.90 and a 1 year high of $5.64.

Analysts Set New Price Targets

Several research firms have weighed in on CRDF. HC Wainwright decreased their price target on shares of Cardiff Oncology from $18.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.63.

Hedge Funds Weigh In On Cardiff Oncology

Several institutional investors have recently bought and sold shares of CRDF. Geode Capital Management LLC grew its stake in shares of Cardiff Oncology by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock worth $4,723,000 after buying an additional 104,409 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Cardiff Oncology by 189.3% in the 2nd quarter. Bank of America Corp DE now owns 93,393 shares of the company’s stock worth $294,000 after buying an additional 61,110 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Cardiff Oncology by 34.2% in the 2nd quarter. Rhumbline Advisers now owns 84,759 shares of the company’s stock worth $267,000 after buying an additional 21,617 shares in the last quarter. Glenview Trust co grew its stake in shares of Cardiff Oncology by 79.9% in the 2nd quarter. Glenview Trust co now owns 43,128 shares of the company’s stock worth $136,000 after buying an additional 19,150 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Cardiff Oncology by 50.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,319 shares of the company’s stock worth $108,000 after buying an additional 11,497 shares in the last quarter. 16.29% of the stock is owned by hedge funds and other institutional investors.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.